Mobilization of primitive haemopoietic progenitor cells and stem cells with long‐term repopulating ability into peripheral blood in mice by pegylated recombinant human megakaryocyte growth and development factor

• Published in: British journal of haematology 1998-12, Vol.103 (4), p.1172-1180
• Main Authors: Torii, Yoshifumi, Nitta, Yuko, Akahori, Hiromichi, Tawara, Tomonori, Kuwaki, Tomoaki, Ogami, Kinya, Kato, Takashi, Miyazaki, Hiroshi
• Format: Article
• Language: English
• Subjects: Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy; Animals; Biological and medical sciences; Bone marrow, stem cells transplantation. Graft versus host reaction; Cells, Cultured; Dose-Response Relationship, Drug; Female; granulocyte colony‐stimulating factor; Hematopoiesis - drug effects; Hematopoiesis - radiation effects; Hematopoietic Stem Cell Mobilization - methods; Hematopoietic Stem Cell Transplantation - methods; Hematopoietic Stem Cells - cytology; Humans; Male; Medical sciences; megakaryocyte growth and development factor; Mice; mobilization; peripheral blood progenitor cell; thrombopoietin; Thrombopoietin - pharmacology; Transfusions. Complications. Transfusion reactions. Cell and gene therapy
• ISSN: 0007-1048; 1365-2141
• DOI: 10.1046/j.1365-2141.1998.01113.x

We investigated in detail the effect of pegylated recombinant human megakaryocyte growth and development factor (PEG‐rHuMGDF) on peripheral blood progenitor cell (PBPC) mobilization in male BDF1 mice. Treatment with PEG‐rHuMGDF for 5 d stimulated a striking expansion of the circulating levels of multiple types of colony‐forming units in culture (CFU‐c), including CFU‐granulocyte‐macrophage, CFU‐megakaryocyte, burst‐forming units‐erythroid, and multipotent CFU‐c, and primitive day‐12 CFU‐spleen. All of these progenitors were mobilized into the peripheral blood (PB) with similar kinetics; their numbers peaked after the cessation of treatment and then declined earlier than platelet numbers peaked. The maximal increase in any of the four CFU‐c in the PB was attained with at least 300 μg/kg/d of PEG‐rHuMGDF, whereas peripheral platelet counts plateaued at 30 μg/kg/d. Adoptive transfer with PB from PEG‐rHuMGDF‐treated donor mice resulted in greater survival of lethally irradiated recipients. The majority of the recipients that survived at 187 d after transplantation with PEG‐rHuMGDF‐mobilized PB showed significant donor engraftment at the progenitor cell level. The combined administration of appropriate doses of PEG‐rHuMGDF and recombinant human granulocyte colony‐stimulating factor induced a synergistic increase in the circulating levels of the four CFU‐c compared to either factor alone. These results indicate that PEG‐rHuMGDF as a single agent can mobilize a full spectrum of PBPCs in mice.